Keung Lee, MD
Internal Medicine · Greensboro, NCNPI 1932186301
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,769 of the $11,758 with a category attached, or 74.6%. 57 manufacturers reported payments, led by Bayer at 25.5% of the total. Reporting peaked in 2020 at $4,010 and has fallen 82.0% since, to $722 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$3K
- AstraZeneca$953
- Novo Nordisk$850
- AbbVie$677
- Pfizer$558
- Lilly USA, LLC$554
- plus $5K from 51 others
Across 896 payments — averaging $5731.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$2M
- Boehringer Ingelheim$1.3M
- AbbVie$844K
- Pfizer$499K
- Kowa Research Institute, Inc.$268K
- Esperion Therapeutics, Inc.$236K
- plus $34K from 3 others
What the payments were for
- Consulting fees$2,78124%
- Food & beverage$8,76975%
- Education$2082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,758 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $113,323 |
| JanuviaSitagliptin Phosphate | 93 | $83,723 |
| EliquisApixaban | 109 | $74,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $57,991 |
| XareltoRivaroxaban | 66 | $54,951 |
| JardianceEmpagliflozin | 21 | $27,668 |
| MounjaroTirzepatide | 22 | $25,223 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $21,959 |
| LinzessLinaclotide | 32 | $20,330 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $18,329 |
| FarxigaDapagliflozin Propanediol | 18 | $17,810 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,910 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 55 | $13,980 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $13,805 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $850 | $119,149129 claims |
| MerckJanuvia | $118 | $83,72393 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $289 | $76,815117 claims |
| PfizerEliquis | $558 | $74,312109 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $329 | $58,71070 claims |
| Johnson & JohnsonXarelto | $265 | $54,95166 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $953 | $39,94882 claims |
| Lilly USA, LLCMounjaro | $554 | $25,22322 claims |
| AbbVieLinzess | $677 | $20,33032 claims |
| Orexo US, Inc.Zubsolv | $124 | $13,98055 claims |
| Astellas Pharma US IncMyrbetriq | $191 | $10,74112 claims |
| Indivior Inc.Suboxone | $16 | $8,36345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Greensboro
- Thomas BellGreensboro$29K
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.